Clinical Trials Logo

Filter by:
NCT ID: NCT00572364 Completed - Clinical trials for Advanced Solid Malignancies

Open Label, Dose Escalation Phase I Study of AZD2281

Start date: November 2007
Phase: Phase 1
Study type: Interventional

The purpose of the study is to assess the safety and tolerability of AZD2281 following single and multiple oral doses in patients in Japan with advanced solid malignancies

NCT ID: NCT00571831 Completed - Clinical trials for on the Incidence of Cystoid Macular Edema

The Effect of a Blue Light Filtering IOL

Start date: February 2003
Phase: N/A
Study type: Interventional

To compare the effect on blood retinal barrier disruption 3 and 12 months after implantation of either a blue light filtering intraocular lens(blue-filtering IOL) or an ultraviolet light filtering intraocular lens(UV-filtering IOL).

NCT ID: NCT00571649 Completed - Clinical trials for Venous Thromboembolism

Venous Thromboembolic Event (VTE) Prophylaxis in Medically Ill Patients

MAGELLAN
Start date: December 2007
Phase: Phase 3
Study type: Interventional

This study will evaluate if extended therapy with oral rivaroxaban can prevent blood clots in the leg and lung that can occur with patients hospitalized for acute medical illness, and compare these results with those of the standard enoxaparin dose and duration regimen. The safety of rivaroxaban will also be studied.

NCT ID: NCT00569946 Completed - Clinical trials for Carcinoma, Renal Cell

Study Of AG-013736 (Axitinib) As Second-Line Treatment In Patients With Metastatic Renal Cell Cancer (mRCC)

Start date: December 12, 2007
Phase: Phase 2
Study type: Interventional

To investigate objective tumor response of AG-013736 for metastatic Renal Cell Cancer (mRCC)

NCT ID: NCT00569790 Completed - Colorectal Cancer Clinical Trials

Phase II Trial of Combination Therapy With Irinotecan, S-1, and Bevacizumab (IRIS/Bev) in Patients With Unresectable or Recurrent Colorectal Cancer

Start date: October 2007
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine whether irinotecan, S-1, and bevacizumab are safe in the treatment of unresectable or recurrent colorectal cancer

NCT ID: NCT00569699 Completed - Colorectal Cancer Clinical Trials

Phase II Trial of Combination Therapy With Bevacizumab and S-1 in Elderly Patients With Unresectable or Recurrent Colorectal Cancer (BASIC)

Start date: October 2007
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine whether S-1 and bevacizumab are safe in the treatment of unresectable or recurrent colorectal cancer

NCT ID: NCT00569335 Completed - Colorectal, Cancer Clinical Trials

Phase II Trial of Combination Therapy With S-1, Irinotecan, and Bevacizumab (SIRB) in Patients With Unresectable or Recurrent Colorectal Cancer

Start date: October 2007
Phase: Phase 2
Study type: Interventional

Phase II trial of combination therapy with S-1, irinotecan, and bevacizumab (SIRB) in patients with unresectable or recurrent colorectal cancer

NCT ID: NCT00568516 Completed - Prostatic Neoplasms Clinical Trials

Phase II Study of ASP3550 in Patients With Prostate Cancer

Start date: October 2007
Phase: Phase 2
Study type: Interventional

To assess the effect of ASP3550 on the maintenance of serum testosterone suppression in patients with prostate cancer

NCT ID: NCT00568022 Completed - Breast Cancer Clinical Trials

A Phase I Study of Ixabepilone in Combination With Capecitabine in Japanese Patients With Metastatic Breast Cancer

Start date: February 2008
Phase: Phase 1
Study type: Interventional

The purpose of this study is to determine the dose-limiting toxicity (DLT), maximum tolerated dose (MTD) and recommended Phase II dose of ixabepilone in combination with capecitabine in Japanese participants with metastatic breast cancer.

NCT ID: NCT00567918 Completed - Conjunctivitis Clinical Trials

Phase III, Long-Term, Open-Label, Extension Study of 0.1% Tacrolimus(FK506) Ophthalmic Suspension in Patients With Vernal Keratoconjunctivitis

Start date: May 2004
Phase: Phase 3
Study type: Interventional

To investigate the long-term efficacy and safety of FK506 ophthalmic suspension in patients with vernal keratoconjunctivitis